Treatment
Upadacitinib clinical trials
We’re tracking 35 recruiting studies that include Upadacitinib, each written for real people, not researchers, below.
Recruiting studies
- NCT07588568RecruitingPhase 2
Testing upadacitinib for EoE that doesn't respond to steroids
This study tests a pill called upadacitinib (a JAK inhibitor) in people with eosinophilic esophagitis (EoE) that hasn't improved with swallowed steroids. It aims to see if the drug can reduce inflammation and symptoms in the esophagus when added to your current steroid treatment.
Chapel Hill, North CarolinaAges 18–65 - NCT07442045Recruiting
Comparing combined vs single drug for ulcerative colitis
Researchers want to see if taking two medications together (upadacitinib and vedolizumab) works better than taking just upadacitinib alone for people with moderate to severe ulcerative colitis. This is a real-world study, meaning it looks at patients being treated in normal medical practice.
Foshan, GuangdongAges 18 years+ - NCT07258771RecruitingPhase 4
Upadacitinib plus steroids vs steroids alone for severe ulcerative colitis
This trial tests if adding upadacitinib (a pill) to standard steroid treatment helps people with a severe flare of ulcerative colitis feel better faster. You may qualify if you are having frequent bloody stools and signs of serious inflammation, and you haven't tried upadacitinib before.
Ann Arbor, MichiganAges 18–75 - NCT06389136RecruitingPhase 3
Study of upadacitinib for eczema after dupilumab didn't work
This trial tests if a pill called upadacitinib (a JAK inhibitor) can help adults with moderate-to-severe atopic dermatitis (eczema) that didn't improve enough with dupilumab. You may be able to join if your eczema is still active despite using dupilumab for at least 4 months.
Birmingham, AlabamaAges 18–63 - NCT07843693RecruitingPhase 1
Testing three arthritis drugs in healthy volunteers
This trial tests three arthritis medications in healthy people to understand how safe they are and how the body processes them. It may help in developing future treatments for conditions like rheumatoid arthritis.
Grayslake, IllinoisAges 18–65 - NCT07772492RecruitingPhase 3
Study of upadacitinib for teens with severe hair loss
This study tests if upadacitinib can help young people with severe alopecia areata (a condition causing patchy hair loss) regrow their hair. It may be an option if hair loss has been present for less than 8 years and there has been no recent improvement.
Los Angeles, CaliforniaAges 6–17 - NCT07546097RecruitingPhase 4
Upadacitinib vs Steroids for Severe Ulcerative Colitis
This study compares a newer medication called upadacitinib to traditional steroids for treating acute severe ulcerative colitis (sudden worsening of UC with bloody diarrhea and urgent symptoms). The goal is to see which approach works better as a first treatment.
Ankang, ShaanxiAges 18–85 - NCT07550673RecruitingPhase 4
Upadacitinib vs. Infliximab for Severe Ulcerative Colitis
This study compares two medications—upadacitinib and infliximab—as second-line treatments for acute severe ulcerative colitis (a serious flare of inflammatory bowel disease). The trial will help doctors understand which treatment works better when standard first-line therapy hasn't controlled the inflammation.
Ankang, ShaanxiAges 18–85 - NCT06454461Recruiting
Testing upadacitinib for stable vitiligo
This trial tests a daily pill (upadacitinib) to see if it can improve vitiligo after an initial treatment (NECS). It is for people whose vitiligo is stable and covers a limited area.
Changchun, JilinAges 18–60 - NCT07510191RecruitingPhase 4
Comparing two ways to treat Crohn's disease if TNFi isn't working well
This trial tests if adding a low dose of a newer pill (upadacitinib) to your current TNF inhibitor (TNFi) works better than increasing the dose of your TNFi alone. It is for people with Crohn's disease who have had some improvement on their TNFi but still have active disease.
Guangzhou, GuangdongAges 18–65 - NCT07492251RecruitingPhase 2
Upadacitinib for erosive lichen planus and lichen planopilaris
This trial tests a pill called upadacitinib to see if it can reduce painful mouth sores and scalp hair loss caused by lichen planus. It may help people who have not gotten better with topical steroid creams.
Nice, Alpes MaritimesAges 18–65 - NCT06780683Recruiting
Testing upadacitinib for inflammatory bowel disease
This study tests a medication called upadacitinib for people with inflammatory bowel disease (ulcerative colitis or Crohn's). The goal is to see how well it works and if it's safe.
Guangzhou, GuangdongAges Any age - NCT06873100RecruitingPhase 1/Phase 2
Upadacitinib for relapsing polychondritis
This trial tests whether upadacitinib, an oral medication, is safe and effective for people with relapsing polychondritis that hasn't improved enough with standard treatments. It aims to reduce inflammation and control symptoms.
Beijing, Beijing MunicipalityAges 18–70 - NCT06902987RecruitingPhase 1
Upatinib for anal fistulas in Crohn's disease
This trial tests whether upatinib can help heal active anal fistulas in people with moderate to severe Crohn's disease. If you have an anal fistula that is causing pain or drainage, this study may offer a new treatment option.
Guangzhou, GuangdongAges 18–70 - NCT06928272RecruitingPhase 3
Long COVID drug study for adults 18 to 65
This study tests whether a commonly used drug (repurposed) can help improve Long COVID symptoms like fatigue, breathing problems, or brain fog. It is for adults 18 to 65 who had COVID-19 in the past 4 years and still have symptoms after 3 months.
San Diego, CaliforniaAges 18–65 - NCT06684522RecruitingEarly Phase 1
Upadacitinib for stubborn eyelid dermatitis
This study tests if the medication upadacitinib can help people whose eyelid rash has not improved with prescription creams. It's for adults who have had eyelid dermatitis for at least two months and have tried at least one prescribed cream that didn't work.
Chicago, IllinoisAges 18–70 - NCT06520397RecruitingPhase 4
Combination therapy vs. higher dose ustekinumab for Crohn's
This trial tests whether a combination of two drugs (upadacitinib and ustekinumab) works better than a higher dose of ustekinumab alone for people with active Crohn's disease that hasn't responded well to previous treatments.
Guangzhou, GuangdongAges 18–70 - NCT06461897RecruitingPhase 3
Comparing upadacitinib to dupilumab for eczema in children
This study tests whether an oral medicine (upadacitinib) works as well as a shot (dupilumab) for children aged 2 to 12 with moderate to severe eczema. It aims to see which treatment better controls symptoms like itching and skin rashes.
Little Rock, ArkansasAges 2–11 - NCT06454188RecruitingPhase 4
Upadacitinib for Psoriatic Arthritis with Spine Involvement
This study tests how well upadacitinib (a pill taken daily) works for people with active psoriatic arthritis that also affects the spine. It is for those who have not responded well enough to other treatments like NSAIDs or biologics.
Cleveland, OhioAges 18 years+ - NCT06332534RecruitingPhase 3
Upadacitinib in children with moderate to severe Crohn's disease
This study tests an oral pill called upadacitinib for children with moderate to severe Crohn's disease that hasn't responded well to other treatments. It aims to see if the medicine can reduce inflammation and improve symptoms safely.
Oakland, CaliforniaAges 2–17 - NCT06227910RecruitingPhase 3
Study of vedolizumab with or without upadacitinib for Crohn's disease
This trial tests combining two medicines, vedolizumab and upadacitinib, to see if they work better together than vedolizumab alone for people with moderate to severe Crohn's disease that hasn't responded well to other treatments.
La Jolla, CaliforniaAges 18–65 - NCT06095596Recruiting
Combining vedolizumab and upadacitinib for ulcerative colitis
This trial tests whether two medications, vedolizumab (a biologic given by IV) and upadacitinib (a pill), work together to help people with moderate to severe ulcerative colitis. The goal is to see if this combination is safe and effective for controlling symptoms and healing the colon.
Guangzhou, GuangdongAges 18 years+ - NCT06012240RecruitingPhase 3
Testing Upadacitinib for Severe Alopecia Areata
This study tests an oral tablet called upadacitinib for people with severe alopecia areata who have lost at least half of their scalp hair. It aims to see if the drug can safely help hair regrow.
Birmingham, AlabamaAges 12–63 - NCT05609630RecruitingPhase 3
Testing two medicines for active systemic juvenile arthritis
This Phase 3 trial studies how well upadacitinib (a pill) and tocilizumab (a shot/IV medicine) improve symptoms and inflammation in children with active systemic juvenile idiopathic arthritis (sJIA). It also looks at side effects and how these medicines move through the body.
Phoenix, ArizonaAges 1–17
What Upadacitinib is being studied for
Conditions with recruiting Upadacitinib studies.
Common questions
- Are there clinical trials studying Upadacitinib?
- Yes. Clin2 currently lists 35 recruiting studies that include Upadacitinib, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Upadacitinib trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Upadacitinib an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Upadacitinib or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.